← All trials
NCT05945615
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Aug 31, 2024
- Completion date
- Nov 30, 2024
- First posted
- Jul 14, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pennsylvania State UniversityLead sponsor
- Pennsylvania State UniversityOverall official - principal investigator
- Pennsylvania State UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.